FDA issues new monkeypox information for blood establishments

Aug. 15, 2022
FDA regulatory update from AABB.

In response to concerns about the increase in monkeypox cases, the Food and Drug Administration released a new safety and availability communication for the blood community, reiterating that existing safeguards provide sufficient protection against the potential for transfusion-transmission of monkeypox and ensure the continued safety and security of the blood supply. 

“Given the robustness of the existing safeguards for blood safety FDA does not recommend that blood establishments ask donors additional, specific questions about possible exposure to monkeypox virus,” the agency stated. “Further, FDA does not recommend using laboratory diagnostic tests to screen blood donors for monkeypox virus.”   

FDA reiterated that there have been “no reports of transmission of monkeypox virus through blood transfusion” and that “the risk of transfusion-transmission [of monkeypox] remains theoretical.”     

AABB release

ID 328976828 © Olga Korshunova | Dreamstime.com
dreamstime_xxl_328976828
ID 170384413 © Transversospinales | Dreamstime.com
dreamstime_xxl_170384413
ID 37133157 © Tyler Olson | Dreamstime.com
dreamstime_xxl_37133157
ID 267733296 © Yuri Arcurs | Dreamstime.com
dreamstime_xxl_267733296
ID 177061230 © Valerii Honcharuk | Dreamstime.com
dreamstime_xxl_177061230